A M Tonkin

Summary

Affiliation: National Heart Foundation
Country: Australia

Publications

  1. ncbi request reprint "Stress" and coronary heart disease: psychosocial risk factors
    Stephen J Bunker
    National Heart Foundation, 411 King Street, West Melbourne, VIC 3003, Australia
    Med J Aust 178:272-6. 2003
  2. ncbi request reprint Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study
    A M Tonkin
    National Heart Foundation of Australia, Melbourne, Victoria
    Lancet 356:1871-5. 2000
  3. ncbi request reprint Clinical relevance of statins: their role in secondary prevention
    A M Tonkin
    University of Melbourne, Parkville, VIC 3003, Australia
    Atheroscler Suppl 2:21-5. 2001
  4. ncbi request reprint Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study
    Andrew M Tonkin
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
    Am Heart J 151:1305-12. 2006
  5. ncbi request reprint Risk prediction: increasingly important, but questions still remain
    Andrew M Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
    Curr Atheroscler Rep 5:1-2. 2003
  6. doi request reprint The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study
    Malcolm J West
    University of Queensland, Brisbane, Australia
    Eur Heart J 29:923-31. 2008
  7. ncbi request reprint Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
  8. ncbi request reprint White blood cell count predicts reduction in coronary heart disease mortality with pravastatin
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 111:1756-62. 2005
  9. ncbi request reprint Statins for stroke prevention: disappointment and hope
    Pierre Amarenco
    Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Denis Diderot University Paris VII, 46 rue Henri Huchard, 75018 Paris, France
    Circulation 109:III44-9. 2004
  10. ncbi request reprint Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin
    Malcolm J West
    Prince Charles Hospital, Brisbane, Australia
    J Hypertens 20:2513-7. 2002

Detail Information

Publications26

  1. ncbi request reprint "Stress" and coronary heart disease: psychosocial risk factors
    Stephen J Bunker
    National Heart Foundation, 411 King Street, West Melbourne, VIC 3003, Australia
    Med J Aust 178:272-6. 2003
    ..The identified psychosocial risk factors should be taken into account during individual CHD risk assessment and management, and have implications for public health policy and research...
  2. ncbi request reprint Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study
    A M Tonkin
    National Heart Foundation of Australia, Melbourne, Victoria
    Lancet 356:1871-5. 2000
    ..In this substudy of LIPID, we compared subsequent cardiovascular risks and the effects of pravastatin in patients with previous unstable angina or previous myocardial infarction...
  3. ncbi request reprint Clinical relevance of statins: their role in secondary prevention
    A M Tonkin
    University of Melbourne, Parkville, VIC 3003, Australia
    Atheroscler Suppl 2:21-5. 2001
    ..The benefits are found in those who have had unstable angina as well as myocardial infarction. These findings strengthen even further the case for much more widespread use of statins in secondary prevention...
  4. ncbi request reprint Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study
    Andrew M Tonkin
    NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
    Am Heart J 151:1305-12. 2006
    ..We compared cost-effectiveness of pravastatin in a placebo-controlled trial in 5500 younger (31-64 years) and 3514 older patients (65-74 years) with previous acute coronary syndromes...
  5. ncbi request reprint Risk prediction: increasingly important, but questions still remain
    Andrew M Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia
    Curr Atheroscler Rep 5:1-2. 2003
  6. doi request reprint The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study
    Malcolm J West
    University of Queensland, Brisbane, Australia
    Eur Heart J 29:923-31. 2008
    ....
  7. ncbi request reprint Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
    Kausik K Ray
    TIMI Study Group, Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:1405-10. 2005
    ..Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients...
  8. ncbi request reprint White blood cell count predicts reduction in coronary heart disease mortality with pravastatin
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 111:1756-62. 2005
    ....
  9. ncbi request reprint Statins for stroke prevention: disappointment and hope
    Pierre Amarenco
    Department of Neurology and Stroke Center, Bichat University Hospital and Medical School, Denis Diderot University Paris VII, 46 rue Henri Huchard, 75018 Paris, France
    Circulation 109:III44-9. 2004
    ..Treatment strategies based on global cardiovascular risk may be most effective. Additional studies in patients representative of the typical stroke population are needed...
  10. ncbi request reprint Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin
    Malcolm J West
    Prince Charles Hospital, Brisbane, Australia
    J Hypertens 20:2513-7. 2002
    ....
  11. ncbi request reprint Genome-wide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2
    Stephen B Harrap
    Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia s harrap physiology unimelb edu au
    Arterioscler Thromb Vasc Biol 22:874-8. 2002
    ..These data imply that a limited number of potent susceptibility genes exist for the acute coronary syndrome. Such genes are likely to be relevant to the combined processes of atherosclerosis, plaque instability, and coronary thrombosis...
  12. ncbi request reprint Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Paul P Glasziou
    c Professor John Simes, NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 177:428-34. 2002
    ..To measure the cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with established ischaemic heart disease and average baseline cholesterol levels...
  13. ncbi request reprint Depression and cardiovascular morbidity and mortality: cause or consequence?
    Ralph A H Stewart
    Green Lane Hospital, Auckland, New Zealand
    Eur Heart J 24:2027-37. 2003
    ..This study assessed whether depressive symptoms were associated with adverse outcomes in people with a history of an acute coronary syndrome, and evaluated possible explanations for such an association...
  14. ncbi request reprint Anthropometric measures and absolute cardiovascular risk estimates in the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study
    Lei Chen
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
    Eur J Cardiovasc Prev Rehabil 14:740-5. 2007
    ..We aimed to establish the most appropriate anthropometric index and its optimal cutoff point for use as an ancillary measure in clinical practice when identifying people with increased absolute cardiovascular risk estimates...
  15. ncbi request reprint Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study
    Ralph A Stewart
    Green Lane Cardiovascular Unit, Auckland City Hospital, Private Bag 92024, Auckland 1030, New Zealand
    N Z Med J 121:11-23. 2008
    ..This study describes differences in cardiovascular risk factors and cardiovascular mortality in Australians and New Zealanders with stable coronary artery disease stratified by socioeconomic status...
  16. doi request reprint Rationale and design of the Home Automatic External Defibrillator Trial (HAT)
    Gust H Bardy
    The Seattle Institute for Cardiac Research, Seattle, WA 98103 4819, USA
    Am Heart J 155:445-54. 2008
    ..The results of the trial should be available in mid 2008...
  17. ncbi request reprint Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors
    Frank M Sacks
    Nutrition Department, Harvard School of Public Health F M S, Boston, Mass 02115, USA
    Circulation 105:1424-8. 2002
    ..We conducted exploratory analyses of participant characteristics, lipid risk factors, and risk reduction in this group...
  18. doi request reprint Home use of automated external defibrillators for sudden cardiac arrest
    Gust H Bardy
    Seattle Institute for Cardiac Research, Seattle, WA 98103 4819, USA
    N Engl J Med 358:1793-804. 2008
    ..Consequently, home use of an automated external defibrillator (AED) might offer an opportunity to improve survival for patients at risk...
  19. ncbi request reprint Alcohol consumption and cardiovascular mortality accounting for possible misclassification of intake: 11-year follow-up of the Melbourne Collaborative Cohort Study
    Linton R Harriss
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
    Addiction 102:1574-85. 2007
    ..To investigate the relationship between usual daily alcohol intake, beverage type and drinking frequency on cardiovascular (CVD) and coronary heart disease (CHD) mortality, accounting for systematic misclassification of intake...
  20. ncbi request reprint Rural and urban differentials in primary care management of chronic heart failure: new data from the CASE study
    Robyn A Clark
    Faculty of Health Sciences, University of South Australia, Adelaide, SA, Australia
    Med J Aust 186:441-5. 2007
    ..To determine whether primary care management of chronic heart failure (CHF) differed between rural and urban areas in Australia...
  21. ncbi request reprint New acute coronary syndromes guidelines--addressing systems issues
    Andrew M Tonkin
    National Heart Foundation of Australia, West Melbourne, Australia
    Heart Lung Circ 15:284-5. 2006
  22. ncbi request reprint Hormone therapy and cardiovascular disease: a systematic review and meta-analysis
    Dianna J Magliano
    Department of Epidemiology and Preventive Medicine, Monash University, Central and Eastern Clinical School, The Alfred Hospital, Melbourne, Australia
    BJOG 113:5-14. 2006
    ..The recent completion of several randomised clinical trials examining the effects of hormone therapy on CVD presents an opportunity to provide a more precise estimate of the cardiovascular risks of hormone therapy...
  23. ncbi request reprint Towards consistency between guidelines and policy: lipid management--2005
    Andrew M Tonkin
    Heart Lung Circ 14:237-8. 2005
  24. ncbi request reprint Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial
    Paul J Nestel
    Baker Heart Research Institute, Melbourne, Australia
    Am J Clin Nutr 81:1322-9. 2005
    ..Patients in Australia and New Zealand (n = 9014) who participated in a large secondary prevention trial had significantly different CHD mortality rates...
  25. ncbi request reprint Cardiovascular risk factors: when should we treat?
    Andrew M Tonkin
    Med J Aust 178:101-2. 2003
  26. ncbi request reprint How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000
    Lei Chen
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Med J Aust 189:319-22. 2008
    ....